# AASLD/EASL Abstract Draft (~250 words, SYNTHETIC DEMO)

> 본 도구는 연구용/참고용입니다. 임상의사결정에 직접 사용하지 마십시오. 생성된 가설은 IRB 승인 및 전문가 검토 후에만 활용하십시오. 유전형 분석 결과는 임상유전학 전문가 해석이 필요합니다.

## Title
Genotype-stratified response to efruxifermin on MASH resolution in East_Asian MASLD: a hypothesis-generating analysis of PNPLA3 rs738409

## Background
MASLD therapy response heterogeneity is incompletely explained by metabolic phenotype. PNPLA3 rs738409 (risk allele G; East_Asian freq 0.42) is a major MASLD modifier but is rarely pre-specified in trial stratification.

## Methods
Using a synthetic 5-dimensional ontology (SNP x drug x outcome x diet x ethnic) with cross-references to PubMed query bank, GWAS Catalog, gnomAD, and ClinicalTrials.gov, we ranked under-explored cells and generated grant-ready hypotheses. A Korean lean MASLD focus mode applies BMI<25, PNPLA3 GG/CG / TM6SF2 minor allele filtering on KASL multicenter cohort metadata.

## Results
Top-ranked hypothesis: PNPLA3 rs738409 x efruxifermin x MASH_resolution x Korean_LF_HC x East_Asian (score 0.93, PubMed n=0, mechanism plausibility 0.80). Korean lean focus mode flagged feasible IIS designs (estimated N>=480 with adequate power).

## Conclusion
A reproducible 5-D ontology surfaces actionable, under-investigated MASLD pharmacogenomic hypotheses. Validation requires IRB-approved prospective stratified trials. All numerical values in this draft are synthetic for tool demonstration.